M a n u s c r i p t 3
The start: an impurity showing anti-HIV activity
When evaluating a number of commercially available cyclam preparations for their potential inhibitory effects on the replication of human immunodeficiency virus (HIV), all these preparations (i.e. JM1498 (Fig. 1) ), as expected, did not show marked anti-HIV activity [1] .
However, one of these preparations proved quite effective, and, on further exploration, this activity appeared to reside in an impurity, which was characterized as a bicyclam in which the two cyclam rings were tethered by a direct carbon-carbon linkage (i.e. JM1657 (Fig. 1 ) [1] . As it did not prove feasible to re-synthesize JM1657, a program was launched to synthesize a bicyclam derivative with the cyclam rings tethered by an aliphatic bridge, the bicyclam derivative with the propyl bridge (i.e. JM2763) being about as active as JM1657 ( Fig. 1) .
A 100-fold increase in potency was noted upon replacing the aliphatic (i.e. propyl) bridge by an aromatic [i.e. 1,4-phenylene-bis(methylene)] bridge, as in JM2987 (Fig. 1) [2] . This compound proved inhibitory to the replication of HIV-1 and HIV-2 at an EC 50 of 0.001-0.007 µg/ml, while not being toxic to the host cells at a concentration of > 500 µg/ml, thus achieving a selectivity index of > 100,000 ( Fig. 1) . Surprisingly, we did not detect any activity with JM2987 against the simian immunodeficiency virus (SIV) strains tested, which at that time (1994) was an enigmatic observation [this enigma was resolved, when several years later (1997) we demonstrated that the bicyclams specifically target the CXCR4 coreceptor of the Tlymphotropic X4 strains, while not being active against the M-macrophage tropic R5 strains (SIV strains apparently belong to this category)]. Being equipotent as the bromide salt (JM2987), the chloride salt (JM3100) ( Fig. 1 ) was then used in all further experiments. The "JM" (for Johnson Matthey) designation was replaced by "AMD" (for AnorMED) when the further development of JM3100 was transferred from Johnson Matthey to AnorMED. From the beginning it was clear that the bicyclam derivatives (including AMD3100) interfered with an early process (viral entry) of the HIV replication cycle that had to be situated after the virus had been adsorbed to the cells but before the (reverse) transcription of the RNA genome [1, 2] .
It proved difficult to generate HIV strains resistant to AMD3100, and, on further analysis, these bicyclam-resistant HIV strains carried multiple mutations in the viral glycoprotein
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A c c e p t e d M a n u s c r i p t 4 (gp120), pointing to gp120 as the putative target for the antiviral activity of AMD3100 [3] . As it turned out, the viral glycoprotein gp120 was only an indirect target, the direct target being CXCR4, the receptor for the CXC chemokine SDF-1 (stromal derived factor), which also functions as the co-receptor (the principal receptor being CD4 ("CD" standing for "cluster of differentiation") for the T-tropic X4 HIV strains.
CXCR4 as the direct target for the action of AMD3100
That the bicyclam AMD3100 interacted with CXCR4 as its direct target was unequivocally shown in a series of papers published in 1997-1998 [4] [5] [6] . More specifically, AMD3100 was demonstrated by Schols and colleagues [5] and Donzella and colleagues [6] to inhibit T-tropic HIV strains by selective antagonization of the SDF-1 chemokine receptor CXCR4. In fact, a nice correlation was found between the inhibitory effects of AMD3100 on (i) HIV-1 replication, (ii) binding of CXCR4 monoclonal antibody and (iii) SDF-1-mediated signal transduction (SDF-1-induced Ca 2+ flux) ( Fig. 2) , as reviewed by De Clercq [7] .
Inhibition of SDF-1-induced Ca 2+ flux actually allows a very rapid (within 1-2 min) measurement of the blockade of CXCR4 by AMD3100 [8] . Thus, within the HIV-1 replicative cycle AMD3100 interferes with the binding of the HIV gp120 to the CXCR coreceptor after it has first been bound to the CD4 receptor, and before the HIV gp41 initiates the fusion of the viral envelope membrane with the cell membrane ( Fig. 3 ) [9, 10] .
As reviewed previously [11] , AMD3100, akin to SDF-1, specifically blocks those (Ttropic) virus strains using CXCR4 as the co-receptor, whereas neither AMD3100 nor SDF-1 exhibit any activity against the M-tropic virus strains using CCR5 as the co-receptor (Table 1) [5]. Vice versa, RANTES (the natural ligand of CCR5) effectively inhibited the M-tropic R5 virus strains, while not being active against the T-tropic R4 virus strains. AMD3100 is a highly specific CXCR4 antagonist inhibiting SDF-1-mediated Ca 2+ flux in a number of cells expressing CXCR4, but has no inhibitory effect on chemokine-induced signalling from CXCR1, CXCR2, CXCR3, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8 or CCR9 [12] . The principal interaction points of AMD3100 with CXCR4 may be the aspartic
Page 5 of 30
A c c e p t e d M a n u s c r i p t 5 acid residues (particularly at positions 171 and 262) located at the extracellular side of CXCR4 ( Fig. 4 ) [13] . Thus, AMD3100 is a specific antagonist of CXCR4, is not crossreactive with other chemokine receptors, and is not an agonist of CXCR4 [14] .
AMD3100 has shown antiviral activity (as measured by p24 production) in SCID-hu Thy/Liv mice infected with a CXCR4-using clinical HIV isolate (reduction of viral load by 0.9 log 10 HIV RNA copies/ml) [15] , and proof of concept (POC) that AMD3100 is also effective in a patient infected with an X4 HIV-1 strain has been provided [16] . This was the only patient in this study that had a purely CXCR4-using virus. Overall, the average change in viral load across all patients was + 0.03 log 10 [17] . AMD3100 has the ability to suppress both X4-tropic and dual (X4 and R5) tropic variants that effectively use CXCR4 to enter the cells [18] .
Stem cell mobilization by AMD3100
When AMD3100 was submitted to phase I clinical trials in normal volunteers (before embarking on the phase II clinical trials to evaluate its antiviral activity in HIV-infected patients), an unexpected side effect was noted: a rapid increase in white blood cell (WBC) counts peaking at 6 hours following the intravenous infusion of AMD3100 [19] (Fig. 5 ). The WBC response was clearly dose-dependent over the dosage range used (10, 20, 40 and 80 µg/kg) ( Fig. 5B ). These results were later confirmed by Lack et al. [20] over a dosage range of 40, 80, 160 and 240 µg/kg ( Fig. 6B ). On closer inspection, the white blood cells mobilized by AMD3100 appeared to carry the marker CD34, and thus could be characterized as hematopoietic stem cells [21] . The kinetics of mobilization of CD34 + cells into the peripheral blood ( Fig. 7 ) [21] with a nadir at 6-9 hours following intravenous administration of AMD3100 was almost identical to that noted for the total white blood cell counts ( Fig. 6B ).
Circulating CD34 + cells increased 5-fold after administration of AMD3100 at 80 µg/kg and 15.5-fold after administration of AMD3100 at 240 µg/kg, both at 9 hours after injection. Myeloid progenitor cells-colony forming unit granulocyte-macrophage (CFU-GM); CFU-granulocyte, eosinophil, monocyte, megakaryocyte (CFU-GEMM); and burst forming Page 6 of 30 A c c e p t e d M a n u s c r i p t 6 units-erythroid showed similar increases in mobilization to the blood with increasing doses of AMD3100 [22] . AMD3100 (administered at 160 µg/kg on day 5) was then found to act synergistically with granulocyte-colony stimulating factor (G-CSF administered at 10 µg/kg/day on days 1-4) [23] . Addition of AMD3100 (to G-CSF) resulted in a tripling of circulating CD34 + cells within 10 hours after administration (2.7-fold increase, range: 1.1-6.9-fold) while no mobilization occurred of B cells, tumor cells, or natural killer T-cell subsets such as CD2, CD3, CD4 or CD8 [24] .
For the collection of CD34 + cells to be used for autologous transplantation, the target number of CD34 + cells is 4.0 x 10 6 /kg. With G-CSF (10 µg/kg/day for 5 days) the number of CD34 + cells collected was 3.73 x 10 6 /kg; with AMD3100 (240 µg/kg on day 5), the number of CD34 + cells collected was 3.02 x 10 6 /kg; with both G-CSF (10 µg/kg/day for 5 days) and AMD3100 (160 µg/kg on day 5) combined, the number of CD34 + cells collected was 9.88 x 10 6 /kg [23] . Broxmeyer and colleagues [25] confirmed that AMD3100 induced a rapid mobilization of hematopoietic progenitor cells (HPCs) and synergistically augmented G-CSFinduced mobilization of HPCs. Flomenberg et al. [26] further ascertained that the combination of AMD3100 plus G-CSF is generally safe, effective, and superior to G-CSF alone for autologous HPC mobilization. Furthermore, the CD34 + peripheral blood progenitor cells (PBPCs) mobilized by AMD3100 in combination with G-CSF express significantly higher amounts of genes that potentially promote superior engraftment after myeloablative therapy than G-CSF-mobilized CD34 + PBPCs [27] . Indeed, AMD3100 mobilizes a population of hematopoietic stem cells with intrinsic characteristics different from those hematopoietic stem cells mobilized with G-CSF, suggesting that the mechanism of AMD3100-mediated hematopoietic stem cell mobilization is fundamentally different from G-CSF-mediated hematopoietic stem cell mobilization [28] .
The ability of AMD3100 to mobilize hematopoietic progenitor stem cells from the bone marrow has been demonstrated in a number of experimental model systems: i.e. both
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A c c e p t e d M a n u s c r i p t 7 autologous and allogeneic peripheral blood mononuclear cells (PBMCs) in dogs [29] ; hematopoietic progenitor stem cells (from the femoral bone marrow) in mice and humans [30] ; and hematopoietic stem cells in Fanconi anemia knockout mice [31] .
Holtan and colleagues reported that AMD3100 not only increases the autograft absolute lymphocyte counts (4.16 x 10 9 lymphocytes/kg versus 0.288 x 10 9 lymphocytes/kg), but also that with a median follow-up of 20 months, no relapses occurred in the AMD3100 group (compared with 15 of 29 in the control group) of non-Hodgkin lymphoma patients after autologous stem cell transplantation [32] . Calandra and colleagues [33] found that AMD3100 when given with G-CSF mobilized a sufficient number of CD34 + cells in non-Hodgkin's lymphoma, multiple myeloma, and Hodgkin's disease patients who could not deliver sufficient cells for autologous transplant following other mobilization regimens [33] . With one dose of AMD3100 (240 µg/kg) by subcutaneous injection, two-thirds of the donors collected an allograft with a number of CD34 + cells sufficient for transplantation [34] , and, in this sense, AMD3100 may provide a more rapid and possibly less toxic and less cumbersome alternative to the traditional G-CSF-based CD34 + cell mobilization in normal donors.
Thus, in conclusion, AMD3100 is a rapid and efficient stem cell-mobilizing agent [35] ; once in the circulating blood, stem cells can be collected for use in autologous stem cell transplantation in patients with haematological malignancies such as multiple myeloma or non-Hodgkin's lymphoma [36] . There is no increased risk that in the patients with multiple myeloma or non-Hodgkin's lymphoma AMD3100 may itself mobilize tumor cells [37] [38] [39] .
Any potential of AMD3100 in the treatment of arthritis, ischemia, cancer or virus infections (other than HIV) ?
To the extent that in the pathogenesis of any given disease the CXCR4 interaction with SDF-1 plays a critical role, AMD3100, as a potent and selective CXCR4 antagonist, may be expected to interfere with the clinical course of this disease. Hence AMD3100 has been found to inhibit collagen-induced arthritis in mice, concomitantly with the inhibition of SDF-1-elicited intracellular Ca 2+ flux in Mac-1 + cells harvested from the spleens of these mice [40] .
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A c c e p t e d M a n u s c r i p t 8 Several human breast cancer cell lines have been found to express CXCR4 [41] , and it is therefore surprising that the potential of AMD3100 in the treatment of breast cancer has not been further followed up in recent years.
Studies of Rubin et al. [42] have shown that systemic administration of AMD3100 inhibits the growth of intracranial glioblastoma and medulloblastoma xenographs. CXCR4 is apparently critical to the progression of diverse brain malignancies, thus providing a scientific rationale for clinical evaluation of AMD3100 in the treatment of malignant brain tumors [42] .
CXCR4 has proven to be essential for the trans-endothelial migration of Waldenstrom macroglobulinemia (WM) cells, and this process is inhibited by AMD3100 [43] . AMD3100 may be useful in future clinical applications in the regulation of trafficking of WM cells and increasing sensitivity to therapeutic agents.
Furthermore, AMD3100 has been shown to effectively reduce tumor growth in nude mice inoculated with anaplastic thyroid carcinoma (ATC) cells and may well represent a novel potential strategy in the treatment of ATC, a rare thyroid cancer with extremely poor prognosis [44] .
CXCR4 and SDF-1 are overexpressed in human pituitary adenomas, and as CXCR4 activation may contribute to pituitary cell proliferation, and, possibly, adenoma development as well, AMD3100 could play a role in suppressing the growth of pituitary adenomas in humans [45] .
AMD3100 has also been reported to decrease invasion of human colorectal cancer cells in vitro [46] . Thus, blocking the interaction of CXCR4 with SDF-1 (CXCL12) may provide a novel means of preventing the invasion and metastasis of colorectal cancer.
AMD3100 is a potent and rapid mobilizer of angiogenic cells [47] , which may stimulate angiogenesis at sites of ischemia through a paracrine mechanism [48] , including ischemia in a diabetic environment [49] .
Recently, McCandless et al. [50] reported that AMD3100 promoted the entry into the CNS parenchyma of CD8 + T-lymphocytes specific for WNV (West Nile virus), reduced viral load within the CNS, and significantly improved survival after WNV infection.
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What about anti-HIV activity of CXCR4 antagonists ? From AMD3100 to AMD070.
Guided by AMD3100 as the prototype, several small-molecule CXCR4 antagonists (i.e. based on two aromatic amine moieties connected by a para-xylylene group) were synthesized, the most effective congener inhibiting the interaction of CXCR4 with SDF-1 at a concentration as low as 1.2 nM [51] .
The identification of AMD070 as a potent, orally bioavailable CXCR4 antagonist which strongly inhibits HIV infectivity (at an EC 50 of 1-10 nM) dates already from more than 5 years ago, but has so far only been communicated in abstract form [52] . AMD070 was found to inhibit X4 HIV replication in 5 different CD4 + T-cell lines, CXCR4-transfected cell lines and peripheral blood mononuclear cells (PBMs). AMD070, akin to AMD3100, had no activity against R5 HIV-1 variants. Unlike AMD3100, AMD070 cannot be considered a bicyclam (Fig. 8 ). The structure of AMD070 was revealed by Kazmierski et al. in their report [53] .
Proof of concept that AMD070 (originally referred to as AMD11070) can selectively inhibit X4-tropic virus in HIV-1-infected patients was provided by Saag and colleagues [54] and Moyle and colleagues [55] . Like AMD3100, AMD070 induced a dose-related elevation of the WBC counts, which can be attributed to CXCR4 blockade. Whether AMD070, which, unlike AMD3100 (which has to be given parenterally) can be administered orally, has any future potential as either an anti-HIV agent, or a stem cell-mobilizing agent, or, possibly, an agent inhibitory to any other CXCR4-mediated process, remains subject of further study.
What is for sure, is that if CRIs (coreceptor inhibitors), whether CXCR4 inhibitors or CCR5 inhibitors, are used as anti-HIV agents, they should be used in combination regimens, so as to prevent selection of CXCR4-using T-tropic variants if only CCR5 inhibitors are used, and to prevent selection of CCR5-using M-tropic variants if only CXCR4 inhibitors are used [56, 57] .
Page 10 of 30
A c c e p t e d M a n u s c r i p t 
Conclusion
The bicyclam AMD3100 represents a typical example of the meandrous path of drug discovery, hopping from one unexpected ("serendipitous") observation to another, ultimately leading to the clinical use for which originally it was neither conceived nor developed.
Bicyclam JM1657 (JM standing for Johnson Matthey) was originally identified as an impurity in a (mono)cyclam preparation evaluated for its potential inhibition of the replication of HIV (human immunodeficiency virus). While most of the commercially available cyclam preparations were virtually inactive against HIV, one particular preparation showed a marked anti-HIV activity, apparently due to an impurity. This impurity was purified and identified as the bicyclam JM1657 (with the 2 cyclam rings tethered through a direct carbon-carbon linkage). While re-synthesis of this compound failed, it was the onset of a large synthetic effort leading first to the synthesis of JM2763 (with the 2 cyclam rings tethered by an aliphatic bridge), and, then to the synthesis of JM3100 (later designated as AMD3100, AMD standing for AnorMED) (with the 2 cyclam rings tethered by an aromatic bridge). AMD3100 was found to inhibit HIV [both HIV-1 and HIV-2, but not SIV (simian immunodeficiency virus)], within the 1-10 nM concentration range while not being toxic to the host cells at concentrations up to 500 µM, thus achieving a selectivity index of approximately 100,000.
The target of action was initially thought to be the viral envelope glycoprotein gp120. It appeared only to be the indirect target. The direct target of action turned out to be the coreceptor CXCR4 used by T-lymphotropic HIV strains to enter the cells (the primary receptor being CD4). Consequently, the anti-HIV activity of AMD3100 was confined to those HIV strains (now referred to as X4 strains) using CXCR4 as co-receptor [the normal ligand for CXCR4 is the chemokine SDF-1 (stromal derived factor), now also referred to as CXCL12].
Initial (phase I) clinical trials undertaken with AMD3100, as a prelude to its development as a candidate anti-HIV drug for the treatment of AIDS, showed an unexpected side effect: an increase in the white blood cell (WBC) counts. On closer inspection it appeared that AMD3100 specifically increased CD34+ (hematopoietic stem) cell counts in the peripheral blood. SDF-1, through its interaction with CXCR4, retains the stem cells in the bone marrow Page 12 of 30 A c c e p t e d M a n u s c r i p t 12 (a process referred to as "homing"). One single parenteral injection of AMD3100 (at a dose of 240 µg/kg) suffices to mobilize the stem cells from the bone marrow into the bloodstream, where they can be collected by leukapheresis. AMD3100 in combination with granulocyte colony-stimulating factor (G-CSF) results in the collection of more progenitor cells than G-CSF alone. AMD3100 is a more rapid mobilizer of hematopoietic stem cells than G-CSF. At present, the major indication for clinical use of AMD3100 (Mozobil TM ) is the mobilization of hematopoietic stem cells from the bone marrow into the circulating blood, from where the stem cells can be harvested for use in transplantation in patients with hematological malignancies such as non-Hodgkin's lymphoma or multiple myeloma. Originally discovered as an anti-HIV agent, then found to specifically act as an antagonist of the chemokine receptor CXCR4, and finally licensed for clinical use as a stem cell mobilizer.
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